Fingerprint
Dive into the research topics of 'A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease
Iris Dotan*, Daniel Rachmilewitz, Stefan Schreiber, Rami Eliakim, C. Janneke Van Der Woude, Asher Kornbluth, Alan L. Buchman, Shimon Bar-Meir, Bernd Bokemeyer, Eran Goldin, Christian Maaser, Uma Mahadevan, Ursula Seidler, Jörg C. Hoffman, Douglas Homoky, Terry Plasse, Barbara Powers, Paul Rutgeerts, Daniel Hommes
*Corresponding author for this work
- Tel Aviv Sourasky Medical Center
- Shaare Zedek Medical Center
- Kiel University
- Rambam Health Care Campus
- Erasmus University Rotterdam
- Icahn School of Medicine at Mount Sinai
- Northwestern University
- Sheba Medical Center at Tel Hashomer
- Ruhr University Bochum
- Hadassah University Medical Centre
- University of Münster
- University of California at San Francisco
- Hannover Medical School
- Charité – Universitätsmedizin Berlin
- Gastroenterology Associates
- Cytokine PharmaSciences, Inc.
- KU Leuven
- Leiden University
Research output: Contribution to journal › Article › peer-review
51
Scopus
citations